Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
126 hedge funds and large institutions have $789M invested in Epizyme, Inc in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 45 increasing their positions, 39 reducing their positions, and 24 closing their positions.
967% more call options, than puts
Call options by funds: $23.5M | Put options by funds: $2.2M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
15% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 39
5% less capital invested
Capital invested by funds: $832M → $789M (-$43.5M)
8% less funds holding
Funds holding: 137 → 126 (-11)
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$7.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.42M |
| 3 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
+$2.3M |
| 4 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$1.87M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.78M |
| 2 |
BlackRock
New York
|
-$4.72M |
| 3 |
Two Sigma Investments
New York
|
-$3.11M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$2.61M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.81M |
EPZM Hedge Fund Activity: Q2 2021 in Review
126 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2021, worth a combined $789M — down 5.2% from $832M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of EPZM and 14 opened new positions — a net loss of 10 holders — while 39 trimmed existing stakes and 45 added.
The largest buyer was Hood River Capital Management, opening a new position worth an estimated $7.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.78M.
- 126 institutional investors held Epizyme, Inc (EPZM) as of Q2 2021, down from 137 in Q1 2021.
- Funds reported $789M of Epizyme, Inc stock for Q2 2021, down 5.2% quarter-over-quarter.
- 14 funds opened new Epizyme, Inc positions in Q2 2021 and 24 closed out, a net change of -10 holders.
- The largest Epizyme, Inc buyer in Q2 2021 was Hood River Capital Management, an estimated $7.2M added.
- The largest Epizyme, Inc seller in Q2 2021 was T. Rowe Price Associates, an estimated $5.78M sold.
Based on aggregated 13F filings for Q2 2021.